Insulin-like growth factor I improves cardiovascular function and suppresses apoptosis of cardiomyocytes in dilated cardiomyopathy

W. L. Lee, J. W. Chen, C. T. Ting, T. Ishiwata, S. J. Lin, Murray Korc, P. H. Wang

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

To investigate how insulin-like growth factor I (IGF-I) modulates cardiovascular function and myocardial apoptosis in heart failure, the therapeutic effects of IGF-I were determined in a canine model of dilated cardiomyopathy. The animals were paced at 220 beats/min, and the left ventricular (LV) chamber became dilated after 2 weeks. A subset of paced dogs was treated with sc injections of IGF-I from week 3 to week 4. After 4 weeks of pacing, untreated paced dogs developed significant ventricular dysfunction. IGF-I-treated paced dogs showed better cardiac output, stroke volume, LV end-systolic pressure, and LV end-diastolic pressure. Moreover, pulmonary wedge pressure and systemic vascular resistance were increased in the untreated group and decreased in the IGF-I-treated group. IGF-I treatment was associated with less thinning of the ventricular wall. Compared with the controls, untreated paced dogs showed increased apoptosis of cardiac muscle cells, which was partially suppressed by IGF-I treatment. The myocardial apoptotic index was negatively related to the thickness of the ventricular wall and to cardiac output, suggesting that ventricular remodeling/dysfunction involves the occurrence of myocardial apoptosis. Due to the close resemblance between this experimental model of dilated cardiomyopathy and human heart failure, the results of this study provide evidence that IGF-I may be a potential therapeutic agent for the failing human heart.

Original languageEnglish (US)
Pages (from-to)4831-4840
Number of pages10
JournalEndocrinology
Volume140
Issue number10
StatePublished - 1999
Externally publishedYes

Fingerprint

Dilated Cardiomyopathy
Insulin-Like Growth Factor I
Cardiac Myocytes
Apoptosis
Dogs
Ventricular Dysfunction
Cardiac Output
Heart Failure
Blood Pressure
Ventricular Remodeling
Pulmonary Wedge Pressure
Therapeutic Uses
Vascular Resistance
Stroke Volume
Canidae
Theoretical Models
Therapeutics
Injections

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Lee, W. L., Chen, J. W., Ting, C. T., Ishiwata, T., Lin, S. J., Korc, M., & Wang, P. H. (1999). Insulin-like growth factor I improves cardiovascular function and suppresses apoptosis of cardiomyocytes in dilated cardiomyopathy. Endocrinology, 140(10), 4831-4840.

Insulin-like growth factor I improves cardiovascular function and suppresses apoptosis of cardiomyocytes in dilated cardiomyopathy. / Lee, W. L.; Chen, J. W.; Ting, C. T.; Ishiwata, T.; Lin, S. J.; Korc, Murray; Wang, P. H.

In: Endocrinology, Vol. 140, No. 10, 1999, p. 4831-4840.

Research output: Contribution to journalArticle

Lee, WL, Chen, JW, Ting, CT, Ishiwata, T, Lin, SJ, Korc, M & Wang, PH 1999, 'Insulin-like growth factor I improves cardiovascular function and suppresses apoptosis of cardiomyocytes in dilated cardiomyopathy', Endocrinology, vol. 140, no. 10, pp. 4831-4840.
Lee, W. L. ; Chen, J. W. ; Ting, C. T. ; Ishiwata, T. ; Lin, S. J. ; Korc, Murray ; Wang, P. H. / Insulin-like growth factor I improves cardiovascular function and suppresses apoptosis of cardiomyocytes in dilated cardiomyopathy. In: Endocrinology. 1999 ; Vol. 140, No. 10. pp. 4831-4840.
@article{e162ac421d124593b01a4c997fba1be2,
title = "Insulin-like growth factor I improves cardiovascular function and suppresses apoptosis of cardiomyocytes in dilated cardiomyopathy",
abstract = "To investigate how insulin-like growth factor I (IGF-I) modulates cardiovascular function and myocardial apoptosis in heart failure, the therapeutic effects of IGF-I were determined in a canine model of dilated cardiomyopathy. The animals were paced at 220 beats/min, and the left ventricular (LV) chamber became dilated after 2 weeks. A subset of paced dogs was treated with sc injections of IGF-I from week 3 to week 4. After 4 weeks of pacing, untreated paced dogs developed significant ventricular dysfunction. IGF-I-treated paced dogs showed better cardiac output, stroke volume, LV end-systolic pressure, and LV end-diastolic pressure. Moreover, pulmonary wedge pressure and systemic vascular resistance were increased in the untreated group and decreased in the IGF-I-treated group. IGF-I treatment was associated with less thinning of the ventricular wall. Compared with the controls, untreated paced dogs showed increased apoptosis of cardiac muscle cells, which was partially suppressed by IGF-I treatment. The myocardial apoptotic index was negatively related to the thickness of the ventricular wall and to cardiac output, suggesting that ventricular remodeling/dysfunction involves the occurrence of myocardial apoptosis. Due to the close resemblance between this experimental model of dilated cardiomyopathy and human heart failure, the results of this study provide evidence that IGF-I may be a potential therapeutic agent for the failing human heart.",
author = "Lee, {W. L.} and Chen, {J. W.} and Ting, {C. T.} and T. Ishiwata and Lin, {S. J.} and Murray Korc and Wang, {P. H.}",
year = "1999",
language = "English (US)",
volume = "140",
pages = "4831--4840",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "10",

}

TY - JOUR

T1 - Insulin-like growth factor I improves cardiovascular function and suppresses apoptosis of cardiomyocytes in dilated cardiomyopathy

AU - Lee, W. L.

AU - Chen, J. W.

AU - Ting, C. T.

AU - Ishiwata, T.

AU - Lin, S. J.

AU - Korc, Murray

AU - Wang, P. H.

PY - 1999

Y1 - 1999

N2 - To investigate how insulin-like growth factor I (IGF-I) modulates cardiovascular function and myocardial apoptosis in heart failure, the therapeutic effects of IGF-I were determined in a canine model of dilated cardiomyopathy. The animals were paced at 220 beats/min, and the left ventricular (LV) chamber became dilated after 2 weeks. A subset of paced dogs was treated with sc injections of IGF-I from week 3 to week 4. After 4 weeks of pacing, untreated paced dogs developed significant ventricular dysfunction. IGF-I-treated paced dogs showed better cardiac output, stroke volume, LV end-systolic pressure, and LV end-diastolic pressure. Moreover, pulmonary wedge pressure and systemic vascular resistance were increased in the untreated group and decreased in the IGF-I-treated group. IGF-I treatment was associated with less thinning of the ventricular wall. Compared with the controls, untreated paced dogs showed increased apoptosis of cardiac muscle cells, which was partially suppressed by IGF-I treatment. The myocardial apoptotic index was negatively related to the thickness of the ventricular wall and to cardiac output, suggesting that ventricular remodeling/dysfunction involves the occurrence of myocardial apoptosis. Due to the close resemblance between this experimental model of dilated cardiomyopathy and human heart failure, the results of this study provide evidence that IGF-I may be a potential therapeutic agent for the failing human heart.

AB - To investigate how insulin-like growth factor I (IGF-I) modulates cardiovascular function and myocardial apoptosis in heart failure, the therapeutic effects of IGF-I were determined in a canine model of dilated cardiomyopathy. The animals were paced at 220 beats/min, and the left ventricular (LV) chamber became dilated after 2 weeks. A subset of paced dogs was treated with sc injections of IGF-I from week 3 to week 4. After 4 weeks of pacing, untreated paced dogs developed significant ventricular dysfunction. IGF-I-treated paced dogs showed better cardiac output, stroke volume, LV end-systolic pressure, and LV end-diastolic pressure. Moreover, pulmonary wedge pressure and systemic vascular resistance were increased in the untreated group and decreased in the IGF-I-treated group. IGF-I treatment was associated with less thinning of the ventricular wall. Compared with the controls, untreated paced dogs showed increased apoptosis of cardiac muscle cells, which was partially suppressed by IGF-I treatment. The myocardial apoptotic index was negatively related to the thickness of the ventricular wall and to cardiac output, suggesting that ventricular remodeling/dysfunction involves the occurrence of myocardial apoptosis. Due to the close resemblance between this experimental model of dilated cardiomyopathy and human heart failure, the results of this study provide evidence that IGF-I may be a potential therapeutic agent for the failing human heart.

UR - http://www.scopus.com/inward/record.url?scp=0033305658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033305658&partnerID=8YFLogxK

M3 - Article

VL - 140

SP - 4831

EP - 4840

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 10

ER -